川宁生物（301301）8月25日主力资金净流出1764.21万元

Group 1 - The core viewpoint of the news is that Chuaning Biological (301301) has experienced a decline in revenue and net profit in its latest quarterly report, indicating potential challenges for the company [1] - As of August 25, 2025, Chuaning Biological's stock closed at 12.73 yuan, with a 1.68% increase and a trading volume of 499,000 hands, amounting to a transaction value of 630 million yuan [1] - The company's latest quarterly report shows total operating revenue of 1.297 billion yuan, a year-on-year decrease of 14.85%, and a net profit attributable to shareholders of 288 million yuan, down 18.26% year-on-year [1] Group 2 - Chuaning Biological has a current liquidity ratio of 2.239, a quick ratio of 1.648, and a debt-to-asset ratio of 23.53% [1] - The company has made investments in 14 enterprises and participated in 42 bidding projects, indicating active engagement in business development [2] - Chuaning Biological holds 9 trademark registrations and has obtained 41 administrative licenses, reflecting its commitment to intellectual property and regulatory compliance [2]